-+ 0.00%
-+ 0.00%
-+ 0.00%

AN2 Therapeutics Plans Phase 2 Epetraborole Trial for Polycythemia Vera

PUBT·10/21/2026 11:02:15
Listen to the news
AN2 Therapeutics Plans Phase 2 Epetraborole Trial for Polycythemia Vera
  • AN2 Therapeutics will present its planned Phase 2 epetraborole trial design at the International Congress on Myeloproliferative Neoplasms on October 29, 2026.
  • The study will evaluate oral epetraborole in patients with phlebotomy-dependent polycythemia vera. The congress runs October 29-30 in Brooklyn, New York.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210700BIZWIRE_USPR_____20261021_BW103616) on October 21, 2026, and is solely responsible for the information contained therein.